Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023167570> ?p ?o ?g. }
- W2023167570 endingPage "1268" @default.
- W2023167570 startingPage "1258" @default.
- W2023167570 abstract "This phase I study evaluated the pharmacokinetics and pharmacodynamics of CEP-11981, an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, in patients with advanced, relapsed, or refractory solid tumors.Oral CEP-11981 dose escalations followed a modified Fibonacci sequence (from 3.0 to 4.2, 5.9, 11.8, 19.7, 29.6, 41.4, 55.0, 73.0, 97.4, and 126.6 mg/m(2)). The maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), tumor response, and safety were evaluated.CEP-11981 was tolerated at doses between 3.0 and 97.4 mg/m(2). The MTD of CEP-11981 was determined to be 97.4 mg/m(2), with DLTs observed at the 126.6 mg/m(2) dose. The DLTs were grade 4 neutropenia in 1 patient and grade 3 T-wave inversion with chest heaviness and fatigue in 1 patient. All 3 events resolved on stopping CEP-11981. The most frequently reported adverse events of any grade were fatigue, nausea, diarrhea, decreased appetite, abdominal pain, back pain, vomiting, constipation, headache, dizziness, and dyspnea. Treatment-related grade 3/4 neutropenia was observed in the highest-dose cohorts (2 patients at 97.4 mg/m(2) and 1 patient at 126.6 mg/m(2)), indicating some off-target inhibition. VEGF inhibition was greatest in the higher-dose groups. Although no patient experienced complete or partial response, 44% patients achieved stable disease when measured at ≥ 6 weeks, which occurred more frequently in cohorts receiving ≥ 73.0 mg/m(2).In patients with recurrent or refractory solid tumors, disease stabilization was achieved. Despite acceptable tolerability of CEP-11981 at the MTD, further development by the sponsor has ceased." @default.
- W2023167570 created "2016-06-24" @default.
- W2023167570 creator A5003107448 @default.
- W2023167570 creator A5037713780 @default.
- W2023167570 creator A5046311492 @default.
- W2023167570 creator A5048568078 @default.
- W2023167570 date "2014-08-26" @default.
- W2023167570 modified "2023-10-02" @default.
- W2023167570 title "An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer" @default.
- W2023167570 cites W1479951257 @default.
- W2023167570 cites W1964187194 @default.
- W2023167570 cites W1973677429 @default.
- W2023167570 cites W1976019207 @default.
- W2023167570 cites W1980160209 @default.
- W2023167570 cites W1985666931 @default.
- W2023167570 cites W1992878563 @default.
- W2023167570 cites W1996810856 @default.
- W2023167570 cites W2017322644 @default.
- W2023167570 cites W2018163797 @default.
- W2023167570 cites W2021908772 @default.
- W2023167570 cites W2022254881 @default.
- W2023167570 cites W2025664345 @default.
- W2023167570 cites W2026184172 @default.
- W2023167570 cites W2029245342 @default.
- W2023167570 cites W2061613118 @default.
- W2023167570 cites W2069417222 @default.
- W2023167570 cites W2076704022 @default.
- W2023167570 cites W2078348571 @default.
- W2023167570 cites W2087620658 @default.
- W2023167570 cites W2088781488 @default.
- W2023167570 cites W2100669312 @default.
- W2023167570 cites W2108409964 @default.
- W2023167570 cites W2113788015 @default.
- W2023167570 cites W2116177733 @default.
- W2023167570 cites W2124606227 @default.
- W2023167570 cites W2132697290 @default.
- W2023167570 cites W2139248078 @default.
- W2023167570 cites W2143743735 @default.
- W2023167570 cites W2145835533 @default.
- W2023167570 cites W2147834058 @default.
- W2023167570 cites W2150971555 @default.
- W2023167570 cites W2157769714 @default.
- W2023167570 cites W2158927044 @default.
- W2023167570 doi "https://doi.org/10.1007/s10637-014-0147-9" @default.
- W2023167570 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4226840" @default.
- W2023167570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25152243" @default.
- W2023167570 hasPublicationYear "2014" @default.
- W2023167570 type Work @default.
- W2023167570 sameAs 2023167570 @default.
- W2023167570 citedByCount "8" @default.
- W2023167570 countsByYear W20231675702016 @default.
- W2023167570 countsByYear W20231675702017 @default.
- W2023167570 countsByYear W20231675702019 @default.
- W2023167570 countsByYear W20231675702021 @default.
- W2023167570 countsByYear W20231675702023 @default.
- W2023167570 crossrefType "journal-article" @default.
- W2023167570 hasAuthorship W2023167570A5003107448 @default.
- W2023167570 hasAuthorship W2023167570A5037713780 @default.
- W2023167570 hasAuthorship W2023167570A5046311492 @default.
- W2023167570 hasAuthorship W2023167570A5048568078 @default.
- W2023167570 hasBestOaLocation W20231675701 @default.
- W2023167570 hasConcept C111113717 @default.
- W2023167570 hasConcept C112705442 @default.
- W2023167570 hasConcept C121608353 @default.
- W2023167570 hasConcept C126322002 @default.
- W2023167570 hasConcept C197934379 @default.
- W2023167570 hasConcept C2776694085 @default.
- W2023167570 hasConcept C2777054765 @default.
- W2023167570 hasConcept C2777063308 @default.
- W2023167570 hasConcept C2778820342 @default.
- W2023167570 hasConcept C2780580376 @default.
- W2023167570 hasConcept C2780852908 @default.
- W2023167570 hasConcept C2781112942 @default.
- W2023167570 hasConcept C71924100 @default.
- W2023167570 hasConcept C90924648 @default.
- W2023167570 hasConceptScore W2023167570C111113717 @default.
- W2023167570 hasConceptScore W2023167570C112705442 @default.
- W2023167570 hasConceptScore W2023167570C121608353 @default.
- W2023167570 hasConceptScore W2023167570C126322002 @default.
- W2023167570 hasConceptScore W2023167570C197934379 @default.
- W2023167570 hasConceptScore W2023167570C2776694085 @default.
- W2023167570 hasConceptScore W2023167570C2777054765 @default.
- W2023167570 hasConceptScore W2023167570C2777063308 @default.
- W2023167570 hasConceptScore W2023167570C2778820342 @default.
- W2023167570 hasConceptScore W2023167570C2780580376 @default.
- W2023167570 hasConceptScore W2023167570C2780852908 @default.
- W2023167570 hasConceptScore W2023167570C2781112942 @default.
- W2023167570 hasConceptScore W2023167570C71924100 @default.
- W2023167570 hasConceptScore W2023167570C90924648 @default.
- W2023167570 hasIssue "6" @default.
- W2023167570 hasLocation W20231675701 @default.
- W2023167570 hasLocation W20231675702 @default.
- W2023167570 hasLocation W20231675703 @default.
- W2023167570 hasLocation W20231675704 @default.
- W2023167570 hasOpenAccess W2023167570 @default.
- W2023167570 hasPrimaryLocation W20231675701 @default.
- W2023167570 hasRelatedWork W130012275 @default.
- W2023167570 hasRelatedWork W2259978766 @default.